From the “You Find a Lot of Stuff on the Web When You’re Bored” Department:
Don’t even know how I came across it, but this is sort of interesting. Addex Pharmaceuticals is in the trial stages of a new drug, ADX10059. One medicine-news site says, “[The drug is] a first-in-class migraine prophylactic which works by inhibiting the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation (NAM). Addex believes mGluR5 may be a key player in a neural process* that initiates migraine headaches. Thus, this approach – inhibiting mGluR5 – may lead to a new class of drugs that addresses the causes of migraine rather than just treating the symptoms.”
- “the major neurotransmitter involved in the initiation and the propagation of the migraine circuit,” as one site puts it]
Addex’ site says this (among other things): Although the triggering events leading to migraine are poorly understood, migraine attacks are believed to be propagated by a positive feedback loop in the brain called the “migraine circuit.” In short, the migraine circuit includes stimulation of the brain cortex, dilation of meningeal blood vessels, inflammation and pain. The migraine circuit is known to involve several brain regions, including the cortex, the trigeminal nucleus caudalis, the trigeminal ganglion, the thalamus and the brain’s superficial blood vessels.
Addex has “postulated that ADX10059 could interrupt the migraine circuit to abort an active attack and potentially prevent an attack from being triggered.”
Be interesting to see where this goes. They didn’t say much about other neuropeptides, though. There seems to be a lot of support for the theory that decreased levels of serotonin and/or norepinephrine are the culprit – at least in some cases.